Gilead Sciences, Inc. (GILD) Shares Sold by S&CO Inc.

S&CO Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 20.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,170 shares of the biopharmaceutical company’s stock after selling 1,599 shares during the quarter. S&CO Inc.’s holdings in Gilead Sciences were worth $437,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the stock. Underhill Investment Management LLC raised its stake in Gilead Sciences by 0.9% during the 2nd quarter. Underhill Investment Management LLC now owns 205,450 shares of the biopharmaceutical company’s stock worth $14,554,000 after acquiring an additional 1,850 shares in the last quarter. Capital Management Corp VA raised its stake in Gilead Sciences by 11.4% during the 2nd quarter. Capital Management Corp VA now owns 129,177 shares of the biopharmaceutical company’s stock worth $9,151,000 after acquiring an additional 13,228 shares in the last quarter. Coastline Trust Co raised its stake in Gilead Sciences by 22.0% during the 2nd quarter. Coastline Trust Co now owns 17,165 shares of the biopharmaceutical company’s stock worth $1,216,000 after acquiring an additional 3,090 shares in the last quarter. Whittier Trust Co. of Nevada Inc. raised its stake in Gilead Sciences by 0.8% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 111,220 shares of the biopharmaceutical company’s stock worth $7,879,000 after acquiring an additional 860 shares in the last quarter. Finally, Kaizen Advisory LLC raised its stake in Gilead Sciences by 142.1% during the 2nd quarter. Kaizen Advisory LLC now owns 3,063 shares of the biopharmaceutical company’s stock worth $217,000 after acquiring an additional 1,798 shares in the last quarter. Hedge funds and other institutional investors own 77.66% of the company’s stock.

A number of research firms have commented on GILD. Barclays dropped their price objective on shares of Gilead Sciences from $95.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, May 2nd. ValuEngine lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 2nd. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “buy” rating and set a $85.00 price objective on the stock in a research note on Thursday, April 19th. Piper Jaffray Companies began coverage on shares of Gilead Sciences in a research note on Wednesday, May 30th. They issued a “buy” rating and a $85.00 price objective on the stock. Finally, Morgan Stanley dropped their price objective on shares of Gilead Sciences from $85.00 to $81.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 2nd. Twelve analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $88.04.

In related news, Director John Francis Cogan sold 5,836 shares of the business’s stock in a transaction dated Friday, May 4th. The shares were sold at an average price of $65.09, for a total transaction of $379,865.24. Following the sale, the director now owns 58,455 shares of the company’s stock, valued at $3,804,835.95. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction dated Tuesday, May 1st. The stock was sold at an average price of $72.19, for a total transaction of $3,609,500.00. Following the sale, the director now directly owns 3,067,762 shares in the company, valued at approximately $221,461,738.78. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 155,836 shares of company stock worth $10,936,365. Company insiders own 1.16% of the company’s stock.

Shares of Gilead Sciences stock opened at $76.81 on Monday. Gilead Sciences, Inc. has a 52-week low of $64.27 and a 52-week high of $89.54. The company has a current ratio of 3.30, a quick ratio of 3.23 and a debt-to-equity ratio of 1.50. The stock has a market cap of $99.87 billion, a PE ratio of 8.97, a PEG ratio of -6.58 and a beta of 1.12.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.56 by $0.35. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. The business had revenue of $5.65 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same period in the previous year, the business posted $2.56 earnings per share. The business’s revenue was down 20.9% compared to the same quarter last year. equities analysts anticipate that Gilead Sciences, Inc. will post 5.84 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 27th. Stockholders of record on Friday, September 14th will be paid a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, September 13th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.97%. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: Should you buy a closed-end mutual fund?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply